Financial Performance - The company's revenue for Q1 2025 was CNY 433,455,447.87, representing a 1.73% increase compared to CNY 426,063,885.00 in the same period last year[5]. - Net profit attributable to shareholders decreased by 71.52% to CNY 8,886,072.24 from CNY 31,199,061.62 year-on-year[5]. - Basic and diluted earnings per share fell by 71.28% to CNY 0.0224 from CNY 0.0780 in the same quarter last year[5]. - Total operating revenue for the current period reached ¥433,455,447.87, an increase from ¥426,063,885.00 in the previous period, reflecting a growth of approximately 0.33%[17]. - Net profit for the current period was ¥8,823,394.93, down from ¥31,199,061.62 in the previous period, indicating a decline of approximately 71.7%[17]. - Total comprehensive income for the period was CNY 8,886,072.24, compared to CNY 31,199,061.62 in the previous period, indicating a significant decrease[19]. - Basic and diluted earnings per share for the current period were CNY 0.0224, down from CNY 0.0780 in the previous period[19]. Cash Flow - The net cash flow from operating activities was negative at CNY -123,588,006.84, a decline of 38.09% compared to CNY -89,497,667.93 in the previous year[5]. - Cash inflow from operating activities totaled CNY 224,202,363.10, compared to CNY 162,314,968.39 in the previous period, reflecting a 38.1% increase[20]. - Cash outflow from operating activities increased to CNY 347,790,369.94 from CNY 251,812,636.32, representing a 38.0% rise[20]. - Net cash flow from investing activities was CNY -281,550,753.27, a decline from CNY 257,209,140.88 in the previous period[21]. - Cash inflow from investing activities was CNY 534,082,862.63, down from CNY 1,346,719,951.55 in the previous period[21]. - Cash inflow from financing activities was CNY 144,970,430.03, compared to CNY 2,248,928.29 in the previous period[21]. - Net cash flow from financing activities improved to CNY 119,768,939.98 from CNY -3,433,915.64 in the previous period[21]. - The ending balance of cash and cash equivalents was CNY 297,473,887.15, down from CNY 521,972,103.32 in the previous period[22]. Assets and Liabilities - Total assets increased by 0.84% to CNY 5,873,745,173.34 from CNY 5,824,923,559.21 at the end of the previous year[5]. - Current assets totaled ¥3,101,788,369.33, an increase from ¥3,046,358,976.71, reflecting a growth of approximately 1.81%[14]. - The total liabilities increased to ¥1,516,179,237.45 from ¥1,463,777,022.00, marking an increase of about 3.57%[16]. - Cash and cash equivalents decreased to ¥437,835,714.18 from ¥745,590,069.83, a decline of approximately 41.2%[14]. - The company's long-term equity investments decreased to ¥198,631,845.90 from ¥203,642,857.22, a decline of about 2.46%[15]. - The company reported a decrease in accounts payable to ¥380,439,647.61 from ¥432,992,431.67, a reduction of about 12.1%[15]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 30,060[9]. - The largest shareholder, Yan Xiaohui, holds 22.15% of the shares, totaling 88,585,200 shares[9]. - The second-largest shareholder, Yin Guoping, owns 16.04% of the shares, amounting to 64,155,000 shares[9]. - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest three being common control persons[9]. - There are no preferred shareholders reported for the period[10]. - The total number of restricted shares at the beginning of the period was 239,060,200, with 825,000 shares released during the period[12]. - The remaining restricted shares at the end of the period are 238,235,200[12]. - The company has a lock-up period for executives, with 25% of their shares eligible for release annually[11]. - The next release date for the majority of restricted shares is September 20, 2026[11]. - There are no changes reported in the participation of major shareholders in margin financing or securities lending[9]. Operating Costs and Expenses - Total operating costs increased to ¥416,830,661.03 from ¥393,251,587.27, representing a rise of about 6.02%[17]. - The company recorded a 41.43% increase in taxes and surcharges, amounting to CNY 3,319,570.38, due to higher tax payments[8]. - Other income rose by 32.46% to CNY 5,274,788.81, primarily driven by increased VAT deductions[8]. - The company experienced a 305.99% increase in non-operating expenses, totaling CNY 573,259.40, mainly due to increased donations[8]. - Research and development expenses rose to ¥16,336,047.27 from ¥15,176,270.87, an increase of approximately 7.65%[17].
宏源药业(301246) - 2025 Q1 - 季度财报